Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Using Various

Laham1, Garcia, Baim

  • 1Angiogenesis Research Center and Interventional Cardiology Section, Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

Current Interventional Cardiology Reports
|November 30, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between neighborhood context, allostatic load, and metabolic dysfunction-associated steatosis liver disease in Mexican-origin farmworkers along the Southern Arizona US/Mexico border.

SSM - population health·2025
Same author

SPONTANEOUS REGRESSION OF A PRIMARY IRIS STROMAL CYST IN A PATIENT WITH KERATOCONUS. A CASE REPORT.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2021
Same author

Inhibition of histamine release from dispersed canine skin mast cells by cyclosporin A, rolipram and salbutamol, but not by dexamethasone or sodium cromoglycate.

Veterinary dermatology·2021
Same author

Short term associations of ambient nitrogen dioxide with daily total, cardiovascular, and respiratory mortality: multilocation analysis in 398 cities.

BMJ (Clinical research ed.)·2021
Same author

Principles of wound care.

Aerztlicher Feldpostbrief·2010
Same author

Case of Aneurism in the Arm, cured by tying the Subclavian Artery.

Medico-chirurgical transactions·2010

Therapeutic angiogenesis uses growth factors like basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) to stimulate new blood vessel growth for ischemic heart disease. Delivery methods and sustained local administration are key for effective treatment.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Ischemic heart disease lacks effective treatments for patients ineligible for revascularization.
  • Therapeutic angiogenesis aims to restore blood flow by promoting new blood vessel formation.
  • Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are key angiogenic agents.

Purpose of the Study:

  • To review preclinical and clinical studies on therapeutic angiogenesis for ischemic heart disease.
  • To evaluate various delivery strategies for angiogenic growth factors.
  • To discuss the potential and limitations of different administration methods.

Main Methods:

  • Review of existing preclinical and clinical studies on bFGF and VEGF.

Related Experiment Videos

  • Analysis of diverse delivery strategies: intracoronary, intravenous, intrapericardial, intramyocardial, and local intravascular/perivascular.
  • Examination of administration techniques: single bolus, repeated, gene therapy, and sustained delivery.

    • Main Results:

    • bFGF and VEGF have demonstrated functionally significant angiogenesis in animal models.
    • Various delivery strategies show promise, but systemic delivery may be limited by recirculation and lack of sustained exposure.
    • Local administration (intrapericardial, intramyocardial) and sustained delivery, including gene therapy, may offer safer and more effective options.

    Conclusions:

    • Therapeutic angiogenesis presents a novel treatment strategy for ischemic heart disease.
    • Optimizing delivery methods, particularly sustained local administration, is crucial for clinical success.
    • Well-designed, randomized controlled trials are necessary to confirm the feasibility and efficacy of myocardial angiogenesis.